410 related articles for article (PubMed ID: 23037494)
1. Evolution of axillary nodal staging in breast cancer: clinical implications of the ACOSOG Z0011 trial.
Shah-Khan M; Boughey JC
Cancer Control; 2012 Oct; 19(4):267-76. PubMed ID: 23037494
[TBL] [Abstract][Full Text] [Related]
2. Effect of Axillary Dissection vs No Axillary Dissection on 10-Year Overall Survival Among Women With Invasive Breast Cancer and Sentinel Node Metastasis: The ACOSOG Z0011 (Alliance) Randomized Clinical Trial.
Giuliano AE; Ballman KV; McCall L; Beitsch PD; Brennan MB; Kelemen PR; Ollila DW; Hansen NM; Whitworth PW; Blumencranz PW; Leitch AM; Saha S; Hunt KK; Morrow M
JAMA; 2017 Sep; 318(10):918-926. PubMed ID: 28898379
[TBL] [Abstract][Full Text] [Related]
3. Locoregional Recurrence After Sentinel Lymph Node Dissection With or Without Axillary Dissection in Patients With Sentinel Lymph Node Metastases: Long-term Follow-up From the American College of Surgeons Oncology Group (Alliance) ACOSOG Z0011 Randomized Trial.
Giuliano AE; Ballman K; McCall L; Beitsch P; Whitworth PW; Blumencranz P; Leitch AM; Saha S; Morrow M; Hunt KK
Ann Surg; 2016 Sep; 264(3):413-20. PubMed ID: 27513155
[TBL] [Abstract][Full Text] [Related]
4. Impact of the American College of Surgeons Oncology Group (ACOSOG) Z0011 trial on clinical management of the axilla in older breast cancer patients: a SEER-medicare analysis.
Caretta-Weyer H; Greenberg CG; Wilke LG; Weiss J; LoConte NK; Decker M; Steffens NM; Smith MA; Neuman HB
Ann Surg Oncol; 2013 Dec; 20(13):4145-52. PubMed ID: 23959051
[TBL] [Abstract][Full Text] [Related]
5. Age and Receptor Status Do Not Indicate the Need for Axillary Dissection in Patients with Sentinel Lymph Node Metastases.
Mamtani A; Patil S; Van Zee KJ; Cody HS; Pilewskie M; Barrio AV; Heerdt AS; Morrow M
Ann Surg Oncol; 2016 Oct; 23(11):3481-3486. PubMed ID: 27169771
[TBL] [Abstract][Full Text] [Related]
6. The Importance of Applying ACOSOG Z0011 Criteria in the Axillary Management of Invasive Lobular Carcinoma: A Multi-institutional Cohort Study.
Roberts A; Nofech-Mozes S; Youngson B; McCready DR; Al-Assi M; Ramkumar S; Cil T
Ann Surg Oncol; 2015 Oct; 22(10):3397-401. PubMed ID: 26215196
[TBL] [Abstract][Full Text] [Related]
7. Potential impact of application of Z0011 derived criteria to omit axillary lymph node dissection in node positive breast cancer patients.
Verheuvel NC; Voogd AC; Tjan-Heijnen VC; Roumen RM
Eur J Surg Oncol; 2016 Aug; 42(8):1162-8. PubMed ID: 27265036
[TBL] [Abstract][Full Text] [Related]
8. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial.
Boughey JC; Suman VJ; Mittendorf EA; Ahrendt GM; Wilke LG; Taback B; Leitch AM; Kuerer HM; Bowling M; Flippo-Morton TS; Byrd DR; Ollila DW; Julian TB; McLaughlin SA; McCall L; Symmans WF; Le-Petross HT; Haffty BG; Buchholz TA; Nelson H; Hunt KK;
JAMA; 2013 Oct; 310(14):1455-61. PubMed ID: 24101169
[TBL] [Abstract][Full Text] [Related]
9. Is Preoperative Axillary Imaging Beneficial in Identifying Clinically Node-Negative Patients Requiring Axillary Lymph Node Dissection?
Pilewskie M; Jochelson M; Gooch JC; Patil S; Stempel M; Morrow M
J Am Coll Surg; 2016 Feb; 222(2):138-45. PubMed ID: 26711795
[TBL] [Abstract][Full Text] [Related]
10. Impact of axillary dissection in women with invasive breast cancer who do not fit the Z0011 ACOSOG trial because of three or more metastatic sentinel lymph nodes.
Bonneau C; Hequet D; Estevez JP; Pouget N; Rouzier R
Eur J Surg Oncol; 2015 Aug; 41(8):998-1004. PubMed ID: 25986854
[TBL] [Abstract][Full Text] [Related]
11. Trade-offs associated with axillary lymph node dissection with breast irradiation versus breast irradiation alone in patients with a positive sentinel node in relation to the risk of non-sentinel node involvement: implications of ACOSOG Z0011.
Krishnan MS; Recht A; Bellon JR; Punglia RS
Breast Cancer Res Treat; 2013 Feb; 138(1):205-13. PubMed ID: 23338762
[TBL] [Abstract][Full Text] [Related]
12. Omission of axillary lymph node dissection for breast cancer patients with three or more positive sentinel lymph nodes.
Prathibha S; White M; Kolbow M; Hui JYC; Brauer D; Ankeny J; Jensen EH; LaRocca CJ; Marmor S; Tuttle TM
Breast Cancer Res Treat; 2024 May; 205(1):127-133. PubMed ID: 38281296
[TBL] [Abstract][Full Text] [Related]
13. [Impact of omission of axillary dissection on adjuvant therapy in patients with metastatic sentinel lymph nodes according to the ACOSOG Z0011 criteria].
Roosen A; Lousquy R; Bricou A; Delpech Y; Selz J; Le Maignan C; Bousquet G; Winterman S; Zelek L; Barranger E
Gynecol Obstet Fertil; 2014 Jun; 42(6):409-14. PubMed ID: 24861437
[TBL] [Abstract][Full Text] [Related]
14. Have the American College of Surgeons Oncology Group Z0011 trial results influenced the number of lymph nodes removed during sentinel lymph node dissection?
Robinson KA; Pockaj BA; Wasif N; Kaufman K; Gray RJ
Am J Surg; 2014 Dec; 208(6):1060-4; discussion 1063-4. PubMed ID: 25312842
[TBL] [Abstract][Full Text] [Related]
15. Which sentinel lymph-node (SLN) positive breast cancer patient needs an axillary lymph-node dissection (ALND)--ACOSOG Z0011 results and beyond.
Gatzemeier W; Mann GB
Breast; 2013 Jun; 22(3):211-6. PubMed ID: 23478200
[TBL] [Abstract][Full Text] [Related]
16. Axillary Dissection and Nodal Irradiation Can Be Avoided for Most Node-positive Z0011-eligible Breast Cancers: A Prospective Validation Study of 793 Patients.
Morrow M; Van Zee KJ; Patil S; Petruolo O; Mamtani A; Barrio AV; Capko D; El-Tamer M; Gemignani ML; Heerdt AS; Kirstein L; Pilewskie M; Plitas G; Sacchini VS; Sclafani LM; Ho A; Cody HS
Ann Surg; 2017 Sep; 266(3):457-462. PubMed ID: 28650355
[TBL] [Abstract][Full Text] [Related]
17. To do or not to do: axillary nodal evaluation after ACOSOG Z0011 Trial.
Humphrey KL; Saksena MA; Freer PE; Smith BL; Rafferty EA
Radiographics; 2014; 34(7):1807-16. PubMed ID: 25384280
[TBL] [Abstract][Full Text] [Related]
18. Omitting axillary lymph node dissection after positive sentinel lymph node in the post-Z0011 era: Compliance with NCCN and ASCO clinical guidelines and Z0011 criteria in a large prospective cohort.
Costaz H; Boulle D; Bertaut A; Rouffiac M; Beltjens F; Desmoulins I; Peignaux K; Ladoire S; Causeret S; Loustalot C; Padeano MM; Vincent L; Jankowski C; Arnould L; Coutant C
Bull Cancer; 2022 Mar; 109(3):268-279. PubMed ID: 34838310
[TBL] [Abstract][Full Text] [Related]
19. Impact of the american college of surgeons oncology group Z0011 criteria applied to a contemporary patient population.
Yi M; Kuerer HM; Mittendorf EA; Hwang RF; Caudle AS; Bedrosian I; Meric-Bernstam F; Wagner JL; Hunt KK
J Am Coll Surg; 2013 Jan; 216(1):105-13. PubMed ID: 23122536
[TBL] [Abstract][Full Text] [Related]
20. Microscopic Extracapsular Extension in Sentinel Lymph Nodes Does Not Mandate Axillary Dissection in Z0011-Eligible Patients.
Barrio AV; Downs-Canner S; Edelweiss M; Van Zee KJ; Cody HS; Gemignani ML; Pilewskie ML; Plitas G; El-Tamer M; Kirstein L; Capko D; Patil S; Morrow M
Ann Surg Oncol; 2020 May; 27(5):1617-1624. PubMed ID: 31820212
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
